Global Psychiatry Collaboration and Licensing Deals Directory, 2019-2024: Deal Trends, Leading Deals by Value, Most Active Dealmakers, Financials Terms, and More
April 26, 2024 10:16 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Psychiatry Collaboration and...
PharmAla Closes Private Placement and Concurrent Debt Settlement
April 19, 2024 08:35 ET
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
April 15, 2024 07:00 ET
|
Axsome Therapeutics, Inc.
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting...
PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta
April 02, 2024 09:30 ET
|
Psychedelics Canada
Psycan announces that Blue Cross Alberta has issued a notice to prescribers that it will reimburse patients for Psychedelic-Assisted Therapy
Beacon Behavioral Partners Celebrates Expansion Across the Southeast United States
February 15, 2024 15:11 ET
|
Beacon Behavioral Partners
Beacon Behavioral Partners, a leading provider of support services for behavioral health practices, announces the success of its expanding network.
Developing Biological Markers to Improve Clinical Care in Autism - A Free Webinar from the Brain & Behavior Research Foundation
February 06, 2024 10:15 ET
|
Brain & Behavior Research Foundation
New York, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
January 30, 2024 09:18 ET
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
Psychiatry Clinic Market Forecast to Reach USD 123.67 Billion by 2030 with Comprehensive Vendor Analysis
January 21, 2024 20:28 ET
|
Research and Markets
Dublin, Jan. 21, 2024 (GLOBE NEWSWIRE) -- The "Global Psychiatry Clinic Market by Age Group (Adult, Pediatric), Therapy Type (Behavioral therapy, Cognitive therapy, Interpersonal therapy) - Forecast...
Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients
January 04, 2024 02:00 ET
|
Nexstim Oyj
Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression...
Understanding Resilience to Schizophrenia through Genetics - A Free Webinar from the Brain & Behavior Research Foundation
December 05, 2023 10:45 ET
|
Brain & Behavior Research Foundation
New York, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Understanding Resilience to Schizophrenia through Genetics” on Tuesday,...